<DOC>
	<DOCNO>NCT02635841</DOCNO>
	<brief_summary>Patients pantothenate kinase-associated neurodegeneration ( PKAN ) complete ApoPharma-sponsored study TIRCON2012V1-EXT wish continue take deferiprone offer opportunity receive compassionate basis . Patients follow locally neurologist appropriate specialist .</brief_summary>
	<brief_title>Compassionate Use Deferiprone Patients With PKAN</brief_title>
	<detailed_description>Patients PKAN complete randomize , blind , placebo-controlled trial TIRCON2012V1 follow-up , single-arm open-label extension study TIRCON2012V1-EXT , may enroll compassionate-use/expanded access program order continue receive iron chelator deferiprone . Participants program follow locally neurologist appropriate specialist . Patients take deferiprone oral solution 80 mg/mL dose prescribe TIRCON2012V1-EXT clinical trial . Safety monitoring patient perform . At minimum , program continue analysis currently blind TIRCON2012V1 trial complete ( approximately Q4 2016 ) , time re-evaluated .</detailed_description>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Completed study TIRCON2012V1EXT 2 . Able adhere program appointment evaluation schedule 3 . Females childbearing potential must negative pregnancy test result start program , unless treat physician determines reasonable risk pregnancy significant incapacity . If applicable , must meet least one follow criterion : Use effective method contraception program 30 day follow last dose deferiprone , OR participate nonheterosexual lifestyle , OR male sexual partner sterilize , OR abstinent program least 30 day completion . 4 . Fertile sexually active heterosexual male must agree use effective method contraception program least 30 day completion 5 . Patients and/or authorized legal representative must provide sign dated write informed consent , minor must additionally sign assent form per local regulatory requirement . Patients exclude take part compassionate use program treating physician determines presence medical , psychological , psychiatric condition his/her opinion would cause participation program unwise</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pantothenate Kinase-Associated Neurodegeneration</keyword>
	<keyword>PKAN</keyword>
	<keyword>Neurodegeneration Brain Iron Accumulation</keyword>
	<keyword>NBIA</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Ferriprox</keyword>
</DOC>